This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $39.41 in the latest trading session, marking a -0.76% move from the prior day.
Moderna Poised to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
When MRNA reports fourth-quarter earnings, investors will likely focus on pipeline updates.
CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.
The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex
by Zacks Equity Research
Amgen, CRISPR, Moderna, Sarepta and Vertex are included in this Analyst Blog.
Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?
by Kanishka Das
On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day.
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?
by Sundeep Ganoria
Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $43.42, moving -1.83% from the previous trading session.
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
by Kinjel Shah
Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy launch progresses.
CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Intellia Loses 21.6% in a Week: How Should You Play the Stock?
by Ekta Bagri
NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
by Sundeep Ganoria
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.36, moving -1.26% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $41.92, moving -1.2% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $39.36, denoting a +1.84% change from the preceding trading day.
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $41.07, representing a +0.32% change from its previous close.
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
by Nalak Das
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.
Intellia Crashes 60% in a Year: How Should You Play the Stock?
by Ekta Bagri
NTLA stock is down significantly in 2024 as investors are not pleased with the recent data from its in vivo CRISPR-based therapies. We advise prospective investors to stay on the sidelines for now.
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
by Ekta Bagri
We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025.
CRISPR Therapeutics (CRSP) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Could Surge 58.3%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 58.3% in CRISPR Therapeutics (CRSP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?
by Sundeep Ganoria
The decline in CRSP's share price could be due to the beating the drug/biotech sector has been taking in the past couple of months, resulting from pipeline setbacks and guidance cuts.
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates. Stock down in pre-market trading.